Virpax Pharmaceuticals Stock Today
| VRPX Stock | USD 0.30 0.01 3.23% |
Performance0 of 100
| Odds Of DistressOver 85
|
Virpax Pharmaceuticals is trading at 0.3 as of the 18th of January 2025; that is 3.23 percent decrease since the beginning of the trading day. The stock's open price was 0.31. Virpax Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 29th of January 2023 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of February 2021 | Category Healthcare | Classification Health Care |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. The company has 4.89 M outstanding shares of which 457.48 K shares are at this time shorted by private and institutional investors with about 1.04 trading days to cover. More on Virpax Pharmaceuticals
Moving together with Virpax Stock
Moving against Virpax Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Virpax Stock Highlights
| CEO Director | Jatinder Dhaliwal | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsVirpax Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Virpax Pharmaceuticals' financial leverage. It provides some insight into what part of Virpax Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Virpax Pharmaceuticals (VRPX) is traded on NASDAQ Exchange in USA. It is located in 1055 Westlakes Drive, Berwyn, PA, United States, 19312 and employs 7 people. Virpax Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.03 M. Virpax Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.89 M outstanding shares of which 457.48 K shares are at this time shorted by private and institutional investors with about 1.04 trading days to cover.
Virpax Pharmaceuticals currently holds about 26.06 M in cash with (9.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Virpax Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAbout 97.4 % of Virpax Pharmaceuticals outstanding shares are held by general public with 2.57 (%) owned by insiders and only 0.03 % by institutional holders.
Check Virpax Ownership Details
Virpax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Garden State Investment Advisory Services Llc | 2024-09-30 | 57.3 K | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 31.4 K | |
| Geode Capital Management, Llc | 2024-09-30 | 28 K | |
| Ubs Group Ag | 2024-09-30 | 20.4 K | |
| Two Sigma Securities, Llc | 2024-09-30 | 12.5 K | |
| Tower Research Capital Llc | 2024-09-30 | 3.8 K | |
| Signature Resources Capital Management, Llc | 2024-09-30 | 50.0 | |
| Bank Of America Corp | 2024-09-30 | 37.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 15.0 | |
| Hantz Financial Services, Inc. | 2024-09-30 | 10.0 |
Virpax Pharmaceuticals Historical Income Statement
Virpax Stock Against Markets
Virpax Pharmaceuticals Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Jeffrey MD | Chief VP | Profile | |
| JD MBA | Chief Officer | Profile | |
| Shana Panzarella | Chief Staff | Profile | |
| Anthony MBA | Chairman CEO | Profile |
Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.